- Published at
- by manilatimes.net
mixed
mixed
News for Eisai Co., Ltd. (ESALY)
- Published at
- by gurufocus.com
positivepositiveAllarity Therapeutics Announces Board Authorization of $5 Million Share Repurchase Program
Boston (March 3, 2025)””Allarity Therapeutics, Inc. (”Allarity” or the ”Company”) ( ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated- Published at
- by gurufocus.com
positivepositiveBiogen Inc (BIIB) and Eisai's Lecanemab Receives Positive Reaffirmation from European Medicines Agency
Biogen Inc (BIIB) and Eisai Co., Ltd. announced on February 28, 2025, that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines A- Published at
- by gurufocus.com
positivepositiveThe Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease
PR NewswireTOKYO and CAMBRIDGE, Mass., Feb. 28, 2025 TOKYO and CAMBRIDGE, Mass., Feb. 28, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: H- Published at
- by gurufocus.com
positivepositiveAllarity Therapeutics Announces Dismissal of Securities Class Action Lawsuit
Boston (February 26, 2025)””Allarity Therapeutics, Inc. (”Allarity” or the ”Company”) ( ALLR), a Phase 2 clinical-stage pharmaceutical company dedicate- Published at
- by gurufocus.com
positivepositiveAllarity Therapeutics to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward FDA Approval in Advanced Ovarian Cancer Patients
Patient enrollment set to begin at leading U.S. clinical trial sites, new drug product already deliveredTrial will advance stenoparib and the stenoparib-DRP C- Published at
- by manilatimes.net
positivepositive- Published at
- by gurufocus.com
neutralneutralQ3 2025 Eisai Co Ltd Earnings Presentation Transcript
Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O N4523.T - Eisai Co LtdQ3 2025 Eisai Co Ltd Earnings PresentationFeb 07, 2025 / 06:00AM GMT ====- Published at
- by seekingalpha.com
mixedmixedEisai Co., Ltd. (ESALF) Q3 2024 Earnings Call Transcript
Eisai Co., Ltd. (OTCPK:ESALF) Q3 2024 Earnings Call Transcript February 7, 2025 1:00 AM ETCompany ParticipantsHaruo Naito - Representative Corporate Officer...- Published at
- by manilatimes.net
positivepositive- Published at
- by insidermonkey.com
positivepositive- Published at
- by manilatimes.net
positivepositive- Published at
- by financialpost.com
positivepositiveUpdate on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union
TOKYO and CAMBRIDGE, Mass., Jan. 31, 2025 (GLOBE NEWSWIRE) — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corpo…- Published at
- by manilatimes.net
mixedmixedA Total of USD 12.7 Million Investment in New Diagnostics and Drug Development for NTDs and Malaria to Partners Including the Ohio State University, PATH, GSK and Others
TOKYO, Jan. 30, 2025 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 2 billion (USD 12.7 million1) in eight projects for the development of new diagnostics and drugs for neglected tropical diseases (NTDs) and malaria.2- Published at
- by gurufocus.com
positivepositiveBiogen Inc (BIIB) Announces FDA Approval for Alzheimer's Treatment LEQEMBI
Biogen Inc (BIIB) and Eisai Co., Ltd. have announced that the U.S. Food and Drug Administration (FDA) has approved a Supplemental Biologics License Application- Published at
- by gurufocus.com
positivepositiveBiogen Inc (BIIB) Announces FDA Approval for New Alzheimer's Treatment Dosing
Biogen Inc (BIIB) and Eisai Co., Ltd. have announced that the U.S. Food and Drug Administration (FDA) has approved a Supplemental Biologics License Application- Published at
- by manilatimes.net
positivepositive- Published at
- by financialpost.com
positivepositive- Published at
- by investing.com
positivepositive- Published at
- by investing.com
mixedmixedFDA Accepts LEQEMBI ® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease By Investing.com
FDA Accepts LEQEMBI ® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease